ArticlesElectronic cigarettes for smoking cessation: a randomised controlled trial
Introduction
Since their launch in 2004, electronic cigarettes (e-cigarettes), a diverse range of battery operated devices that vaporise nicotine for inhalation, have been purchased by millions of people.1 Many smokers use e-cigarettes to help them quit (27% of those making a quit attempt in the UK, in May, 20132), and sales are increasing so rapidly that some analysts predict that they will surpass cigarette sales within a decade.1
The place of e-cigarettes in tobacco control is controversial,3, 4 and there is a paucity of reliable data to inform debate. Available research suggests that e-cigarettes have the potential to assist smokers to quit or reduce smoking: surveys show that many smokers try e-cigarettes for these reasons,5, 6 and studies show that e-cigarettes are capable of delivering nicotine into the bloodstream and attenuating tobacco withdrawal as effectively as nicotine replacement therapy (NRT).7, 8 Use of e-cigarettes also simulates behavioural and sensory dimensions of smoking. However, a trial in 300 smokers unwilling to quit showed low rates of cessation at 12 months for nicotine e-cigarettes and placebo e-cigarettes.9 E-cigarettes also have potential to harm: researchers have detected toxins in e-cigarette fluid and vapour,10 but at much the same concentrations as with NRT and lower than in cigarette smoke;11 a review deemed e-cigarettes to be very unlikely to pose significant risks to smokers.12
In this trial we aimed to assess whether e-cigarettes with cartridges containing nicotine (nicotine e-cigarette) were more effective for smoking cessation than nicotine patches, and included a blind comparison with e-cigarettes containing no nicotine (placebo e-cigarette). We hypothesised that nicotine e-cigarettes would be more effective than patches and placebo e-cigarettes for smoking reduction, tobacco dependence, and relief of withdrawal symptoms, and that they would have no greater risk of adverse events than nicotine patches.
Section snippets
Study design and participants
We did this three parallel group, randomised controlled trial in Auckland, New Zealand. First randomisation was on Sept 6, 2011, and last follow-up was on July 5, 2013. The published protocol describes procedures in detail.13 In brief, people were eligible if they were aged 18 years or older, had smoked ten or more cigarettes per day for the past year, wanted to stop smoking, and could provide consent. We recruited via community newspapers, inviting people to call the study centre for
Results
Of 1293 people who were assessed, 657 were eligible for inclusion in the study (figure 1). 289 people were assigned to nicotine e-cigarettes, 295 to patches, and 73 to placebo e-cigarettes. Participants' baseline characteristics were evenly balanced between treatment groups (table 1). Overall, loss to follow-up was 22%: 17% (48 of 289) in the nicotine e-cigarettes group, 27% (80 of 295) in the patches group, and 22% (16 of 73) in placebo e-cigarettes group.
Verified continuous abstinence at 6
Discussion
13 weeks of nicotine e-cigarette use resulted in increased smoking abstinence at 6 months compared with use of patches or placebo e-cigarettes, but these differences were not statistically significant. Nevertheless, the results were consistent across a range of analyses, and the 95% CIs do not exclude an advantage. In post-hoc analyses using a 5% non-inferiority limit for the risk difference (on the basis of a margin used in our non-inferiority smoking cessation trial of cytisine26), nicotine
References (32)
- et al.
Should e-cigarettes be regulated as a medicinal device?
Lancet Respir Med
(2013) - et al.
Regulatory challenges for refined nicotine products
Lancet Respir Med
(2013) - et al.
Development of a measure of the latency to needing a cigarette
J Adolesc Health
(2011) - et al.
Mouth level exposure using analysis of filters from smoked cigarettes: A study of eight countries
Regul Toxicol Pharmacol
(2011) BAT ramps-up e-cigarette expansion as sales go up in smoke international business times (July 31, 2013)
Smoking toolkit study: monthly tracking of key performance indicators
Electronic cigarettes: a survey of users
BMC Public Health
(2010)- et al.
‘Vaping’ profiles and preferences: an online survey of electronic cigarette users
Addiction
(2013) - et al.
Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial
Tob Control
(2010) - et al.
Electronic cigarettes: effective nicotine delivery after acute administration
Nicotine Tob Res
(2013)
Efficiency and safety of an electronic cigarette (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study
PloS One
Summary of results: laboratory analysis of electronic cigarettes conducted by FDA
Levels of selected carcinogens and toxicants in vapour from electronic cigarettes
Tob Control
Peering through the mist: what does the chemistry of contaminants in electronic cigarettes tell us about health risks? Technical report
Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation
BMC Public Health
The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire
Br J Addict
Cited by (958)
Experimental study on the boiling behavior and film evolution of e-liquid on the surface of porous ceramic in e-cigarette
2024, Applied Thermal EngineeringElectronic Cigarettes are Neither Effective Nor Safe for Quitting Smoking: A Critical View of the Most Recent Meta-Analyses
2024, Archivos de BronconeumologiaSocial media and e-cigarette use: The mediating role of mental health conditions
2024, Journal of Affective DisordersCumulative Exposure to E-Cigarette Coupons and Changes in E-Cigarette Use Among U.S. Adults
2024, American Journal of Preventive Medicine